Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01717482 · ClinicalTrials.gov registry record · Phase 2
Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer
A Phase 2 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT01717482: Clinical Trial Phase 2 study, sponsored by Mayo Clinic.
NCT01717482 is a Phase 2 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01717482, a Phase 2 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to learn whether it is better to receive the drug Metformin with standard of care for lung cancer or just standard of care.
Primary Outcome
To evaluate the feasibility of patient randomization, accrual, and tissue collection in a pilot study of metformin versus observation following resection of stage IA-IIIA lung squamous cell cancer for patients by assessing the reasons patients decline randomization, tracking accrual numbers, and tracking collected tissue and reasons why tissue was not collected.
Interventions
- DRUG Metformin
- OTHER Placebo Comparator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2012-10 |
| Est. Completion | 2019-05-22 |
| Phase | Phase 2 |
Why NCT01717482 stopped before completion
NCT01717482 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Metformin is the first listed.
NCT01717482 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01717482 about?
NCT01717482 is a clinical study titled "Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer". The purpose of this study is to learn whether it is better to receive the drug Metformin with standard of care for lung cancer or just standard of care.
What is the current status of trial NCT01717482?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2012-10. Estimated completion is 2019-05-22.
What interventions are being tested in trial NCT01717482?
The interventions under investigation include: Metformin (DRUG), Placebo Comparator (OTHER).
Who is sponsoring clinical trial NCT01717482?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01717482's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia